Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (August 2023)
25 slides from Cognition Therapeutics's investor presentation, Aug 24, 2023
Slide 1: Disease-modifying medicines for neurodegenerative disorders
Disease-modifying medicines for neurodegenerative disorders Perspective from a pre-Commercial Company August 2023
Slide 2: Agenda for Investor Discussion
2 Confidential • Why we work in age-related neurodegenerative conditions • What we are doing to prepare for Phase 3 clinical trials & commercialization • How we fund our company Agenda for Investor Discussion
Slide 3: Forward-Looking Statements
3 Confidential FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present fa
Slide 4: Multiple Near-term Catalysts
4 Confidential Alzheimer's Development DLB Development GA / Dry AMD Development 2019 2020 2021 2022 2023 2024 2025 Ph2 SHINE (COG0201) Mild-Mod AD Ph2 START (COG0203) Early AD Ph2 SEQUEL (COG0202) qEEG Ph2 SHIMMER (COG1201) DLB Ph2 MAGNIFY (COG2201) GA Topline SHINE Topline SHIMMER Topline IND clear
Slide 5: Cognition Therapeutics – Our Company
5 Confidential • The Why: Our science shows we can impact intractable conditions. Our senior team is driven to treat Alzheimer’s disease and mitigate fear. Commercial executives have developed programs with pharma interest in mind. • The What: Our Pittsburgh Labs were formed to identify specific neu
Slide 6: A Pipeline in a Pill – lead candidate CT1812
6 • Within the amyloid hypothesis, oligomers are a pathogenic form produced early in disease • Innovation lies in blocking toxic oligomer binding and displacing bound oligomers - High degree of blood brain barrier penetration, thus reaches its target - Disease-modifying impact on synapses • Potentia
Slide 7: Our Science The Why:
Our Science The Why:
Slide 8: The Founding Scientists' Goal was to Identify Protective Mechanisms for Neuronal Damage in AD
8 Confidential The Founding Scientists’ Goal was to Identify Protective Mechanisms for Neuronal Damage in AD Platform-enabled product company built on novel library & screening assay Novel phenotypic screening assay >21 DIV primary hippocampal/cortical neuronal cultures in vitro models mature nervou
Slide 9: CT1812 Operates at a Cellular Level to Protect Neurons
9 • Robust scientific legacy has defined biological effects of σ-2 modulation, resulting in new molecules • Behavioral data from in vivo animal models and in vitro studies • CT1812 is in multiple Phase 2 clinical trials • Science vetted through peer-reviewed publications and peer-reviewed NIA grant
Slide 10: CT1812: A Novel Approach Within the Established Amyloid Cascade
10 Confidential Aβ monomer Anti-oligomer Mab CT1812: A Novel Approach Within the Established Amyloid Cascade Anti-protofibril Mab Anti-plaque Mab Protect Synapses: • Small molecule ligand to the σ-2 receptor displaces Aβ oligomers and prevents their binding to synapses Lower Aβ: • Monoclonal antibod
Slide 11: Our MoA Video
11 Confidential Our MoA Video: https://vimeo.com/800999561
Slide 12: Our Target Product Profile and Trials The What:
Our Target Product Profile and Trials The What:
Slide 13: The Evolving AD Market Needs Oral Therapy
13 Confidential • Labeled for initiation of use only in early and mild Alzheimer’s patients • CMS coverage is evolving along with considerations for total cost burden - Therapy - Monitoring requirements / imaging The Evolving AD Market Needs Oral Therapy Recent Breakthroughs include: ✓ Conditional a
Slide 14: Alzheimer's Research Continues to Expand
14 Confidential Alzheimer's Research Continues to Expand New mechanisms being developed 0 25 50 75 100 125 150 Compound MoA Compound MoA 93 Drugs in Development in 2016 (68 are disease modifying) Other Anti-tau Anti-Aβ MAb Small molecule 143 Drugs in Development in 2022 (119 are disease modifying) O
Slide 15: Addresses Patient Care and Caregiver Needs and Economic Burden of Treatment
15 • Routine diagnostic examinations • Once-daily oral therapy • Modest side effect profile • No imaging requirements; reduced associated economics • Limited potential for ARIA • Minimized caregiver burden of administration and monitoring requirements • Strong intellectual property position on key p
Slide 16: Considerations for Potential Pharma Partners
16 Confidential • Clinical trial design consistent with established regulatory endpoints • FDA interactions supportive of trial plans • Strong intellectual property including filings and issued patents • Commercial product profile with competitive differentiation • Well considered pricing strategy C
Slide 17: Conversations Series
17 Confidential "Conversations" Episode 1: Dementia with Lewy Bodies Featuring: • James Galvin, MD, MPH, Univ of Miami Miller School of Medicine Episode 2: Amyloid Lowering Key Insights from Recent Data Featuring: • Christopher H. van Dyck, MD, Yale University School of Medicine • Anton P. Porstei
Slide 18: What We Have Learned From Clinical Trials to Date
18 Confidential What We Have Learned From Clinical Trials to Date Target engagement Anatomical effect Preliminary cognitive improvement Neurophysiology SEQUEL SHINE-A SPARC SNAP1 1 1. AD/PD™ 2022 & LaBarbera, et al. Transl Neurodegener 2023 CT1812 engages target for neuroprotection Demonstrated effe
Slide 19: Our Biomarker Strategy
19 Confidential ✓ Completed: - Unbiased analyses of plasma and CSF samples from: • Phase 1/2 • SHINE Cohort A • SPARC • SHINE A / SPARC pooled • SEQUEL - Identified candidate biomarkers of CT1812 target engagement ❑ Next steps: - Analyze SHINE and SHIMMER clinical data to determine correlation of bi
Slide 20: Phase 2 Program Informs Phase 3 & Regulatory Strategy
20 Confidential • Estimating enrollment of 700-1,500 participants each in two studies - Global enrollment - Randomized 2:1 to CT1812 or placebo - Phase 2 results inform duration of treatment • Stratification with concomitant therapy • Initiate HEOR (heath economics, outcomes research) and pricing re
Slide 21: Support for Research and Clinical Trials The How:
Support for Research and Clinical Trials The How:
Slide 22: NIH Grant Funding
22 Confidential Funding Org Year Project Amount National Institute on Aging (NIH) 2016 COG0101 Ph1b first-in-patient trial for CT1812 $2,410,669 National Institute on Aging (NIH) 2016 COG0102 Ph1b/2a Clinical Trial for CT1812 $2,410,669 National Institute on Aging (NIH) 2017 COG0104 Ph1 SNAP Study:
Slide 23: Financial Position
Financial Position Financials as of June 30, 2023 • Cash and Cash Equivalents: $37.2 million • Expected cash runway through third quarter of 2024 Grant funding for CT1812 studies as of June 30, 2023 • Preclinical through Phase 2: appx $171.0 million − Approximate funding used: ($89.2 million) − Rema
Slide 24: Next Steps: Preparations for Phase 3 & Commercialization
24 Confidential • Develop protocol for prospective biomarker study • Complete dementia trials: mild-moderate Alzheimer’s and DLB • Progress START study in early Alzheimer’s disease • Advance MAGNIFY study in dry AMD • Initiate research on IRA & pricing impact • Conduct KOL panels on product profile
Slide 25: Thank You
Thank You Tony Caggiano, MD, PhD CMO and Head of R&D 914-221-6730 acaggiano@cogrx.com Lisa Ricciardi President & CEO 917-658-5789 lricciardi@cogrx.com John Doyle Chief Financial Officer 603-860-1078 jdoyle@cogrx.com
Cognition Therapeutics — Investor Presentation (August 2023) on 6ix